Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''TRK fusions''' are seen in many solid tumours and have targeted drugs. | '''TRK fusions''' are seen in many solid tumours and have targeted drugs. | ||
Genes | ==General== | ||
*TRK1 | ===Genes=== | ||
*TRK2 | *TRK1. | ||
*TRK3 | *TRK2. | ||
*TRK3. | |||
The TRK genes are tyrosine kinase receptors. | Notes: | ||
*The TRK genes are tyrosine kinase receptors. | |||
*Multiple fusion partners for each gene. | |||
==Classic associations== | |||
== | |||
*[[Mammary analogue secretory carcinoma]] (MASC) - ''ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal | last1 = Lei | first1 = Y. | last2 = Chiosea | first2 = SI. | title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. | journal = Head Neck Pathol | volume = 6 | issue = 2 | pages = 166-70 | month = Jun | year = 2012 | doi = 10.1007/s12105-011-0312-9 | PMID = 22127547 }}</ref> | *[[Mammary analogue secretory carcinoma]] (MASC) - ''ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal | last1 = Lei | first1 = Y. | last2 = Chiosea | first2 = SI. | title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. | journal = Head Neck Pathol | volume = 6 | issue = 2 | pages = 166-70 | month = Jun | year = 2012 | doi = 10.1007/s12105-011-0312-9 | PMID = 22127547 }}</ref> | ||
*[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref> | *[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref> | ||
Revision as of 05:46, 11 September 2018
TRK fusions are seen in many solid tumours and have targeted drugs.
General
Genes
- TRK1.
- TRK2.
- TRK3.
Notes:
- The TRK genes are tyrosine kinase receptors.
- Multiple fusion partners for each gene.
Classic associations
- Mammary analogue secretory carcinoma (MASC) - ETV6-NTRK3.[1]
- Secretory breast carcinoma - ETV6-NTRK3.[2]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.